Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19

Mostrar otras versiones (1)

BACKGROUND: Oral nirmatrelvir/ritonavir (Paxlovid®) aims to avoid severe COVID‐19 in asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and death. Due to its novelty, there are currently few published study results. It remains to be evaluated for which indications an...

Descripción completa

Detalles Bibliográficos
Autores principales: Reis, Stefanie, Metzendorf, Maria-Inti, Kuehn, Rebecca, Popp, Maria, Gagyor, Ildiko, Kranke, Peter, Meybohm, Patrick, Skoetz, Nicole, Weibel, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487421/
https://www.ncbi.nlm.nih.gov/pubmed/36126225
http://dx.doi.org/10.1002/14651858.CD015395.pub2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487421/
https://www.ncbi.nlm.nih.gov/pubmed/36126225
http://dx.doi.org/10.1002/14651858.CD015395.pub2

Ejemplares similares